Genentech, a Roche unit, has partnered with Genesis Therapeutics to utilize Genesis' graph machine learning for enhanced drug discovery and development for an assortment of diseases. As part of the deal, Genesis will be eligible to receive an upfront payment for an undisclosed amount, including royalties on net sales and milestones.
Administration of high-titer convalescent plasma containing neutralizing antibodies in the early stages of COVID-19 reduced viral load in a newly developed African green monkey model of COVID-19 better than low-titer CP or no treatment, according to a study posted before peer review on bioRxiv. Monkeys that received high-titer CP also had the lowest levels of inflammatory markers, blood clotting factors and lung damage, and while low-dose CP was less effective, it also reduced viral load and disease severity.
A compound that mimics the structure of genetic material present in some viruses improved the efficacy of existing immunotherapies in mouse models of human melanoma, according to a study in Science Translational Medicine. The compound, which is now in human trials, makes tumor cells that have stopped producing antigens recognizable to the immune system.
According to data from the AdvaMed COVID-19 testing supply registry, 200 million COVID-19 molecular diagnostic tests have been shipped out in the US. Approximately 1.4 million molecular diagnostic tests are being shipped out each day.
The National Institutes of Health has given Minnetronix Medical a grant to continue its study of its proprietary Neurapheresis cerebrospinal fluid treatment platform, which rapidly removes blood cells and their cytotoxic byproducts that are released into cerebrospinal fluid after an aneurysmal subarachnoid hemorrhage.
Data from a 12-month trial comparing DTM spinal cord stimulation with Medtronic's Intellis platform versus conventional spinal cord stimulation therapy showed positive results. 84% of patients that were treated using Medtronic's DTM system reported at least 50% pain relief, compared with 51% using conventional SCS therapy.
BioReference Laboratories, a unit of OPKO Health, has released its multiplex test that can differentiate influenza A and B and SARS-CoV-2.
The FDA has given 510(k) clearance to Implanet and SeaSpine for their Mariner Cap pedicle-screw stabilization system that is used to treat adult degenerative disorders.
- Page 1